Assess whether to resubmit, meet, or pause the program (9062dd)

SITUATION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — biosimilar analytical similarity report — after a payer demanding RWE the protocol cannot generate. If biosimilar analytical similarity report cannot support to resubmit, meet, or, the only defensible Pharma & Life Sciences output is hold.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. The population in biosimilar analytical similarity report is the one a payer demanding RWE the protocol cannot generate named, so To resubmit, meet, follows for this CMC and Development Pathways file. 2. The population in biosimilar analytical similarity report is adjacent only to a payer demanding RWE the protocol cannot generate; Pause the program is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a payer demanding RWE the protocol cannot generate before biosimilar analytical similarity report arrived; no new CMC and Development Pathways path. 4. Provenance on biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a payer demanding RWE the protocol cannot generate and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for clinical-development physician - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in biosimilar analytical similarity report that a second reviewer can re-perform